Pharmacological targets in inflammation and metabolic diseases

Institute of Biomedicine (IBUB)

Principal investigator: Manuel Vázquez Carrera Researcher: Francisco Javier Palomer Tarrida Investigator Post-Doc: Emma de Juan Barroso Fernández • Marta Montori Grau • María Lucía Peña Moreno • Javier Pizarro Delgado • PhD students FPI: David Aguilar Recarte • Cristina Reguera Moreno

Share on whatsapp
Share on facebook
Share on twitter
Share on linkedin
Share on telegram

Current
Research

Our main research topic is the study of the molecular mechanisms involved in the link between inflammation and insulin resistance. Specifically, we are interested in:

  1. To evaluate the molecular mechanisms by which PPARbeta/delta agonists prevent inflammation and insulin resistance.
  2. To study the molecular mechanisms responsible for metabolic alterations in diabetic cardiomyopathy.
  3. To study how oleic acid prevents saturated fatty acid-induced insulin resistance.
  4. To develop a new ora drug for the treatment of insulin resistance and nonalcoholic fatty liver disease through the increase of hepatic FGF21.

Selected
Publications

Zarei, M.; Barroso, E.; Leiva, R.; Barniol-Xicota, M.; Pujol, E.; Escolano, C.; Vázquez, S.; Palomer, X.; Pardo, V.; González-Rodríguez, Á.; Valverde, Á.M.; Quesada-López, T.; Villarroya, F.; Wahli, W.; Vázquez-Carrera, M. Heme-Regulated eIF2α Kinase Modulates Hepatic FGF21 and Is Activated by PPARβ/δ Deficiency. Diabetes 65:3185-99, 2016. doi: 10.2337/db16-0155.

Zarei, M.; Barroso, E.; Palomer, X.; Dai, J.; Rada, P.; Quesada-López, T.; Escolà-Gil, J.C.; Cedó, L.; Zali, M.R.; Molaei, M.; Dabiri, R.; Vázquez, S.; Pujol, E.; Valverde, Á.M.; Villarroya, F.; Liu, Y.; Wahli, W.; Vázquez-Carrera, M. Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease. Mol. Metab. 8:117-131, 2018. doi: 10.1016/j.molmet.2017.12.008.

Botteri, G.; Montori, M.; Gumà, A.; Pizarro, J.; Cedó, L.; Escolà-Gil, J.C.; Li, D.; Barroso, E.; Palomer, X.; Kohan, A.B.; Vázquez-Carrera, M. VLDL and apolipoprotein CIII induce ER stress and inflammation and attenuate insulin signalling via Toll-like receptor 2 in mouse skeletal muscle cells. Diabetologia 60:2262-2273, 2017. doi: 10.1007/s00125-017-4401-5.

Vázquez-Carrera, M. Unraveling the Effects of PPARβ/δ on Insulin Resistance and Cardiovascular Disease. Trends Endocrinol. Metab. 27:319-334, 2016. doi: 10.1016/j.tem.2016.02.008

Palomer, X.; Capdevila-Busquets, E.; Botteri, G.; Davidson, M.M.; Rodríguez, C.; Martínez-González, J.; Vidal, F.; Barroso, E.; Chan, T.O.; Feldman, A.M.; Vázquez-Carrera, M. miR-146a targets Fos expression in human cardiac cells. Dis. Model Mech. 8:1081-91, 2015. doi: 10.1242/dmm.020768.

Selected
Publications

Author

Identification

Zarei, M.; Barroso, E.; Leiva, R.; Barniol-Xicota, M.; Pujol, E.; Escolano, C.; Vázquez, S.; Palomer, X.; Pardo, V.; González-Rodríguez, Á.; Valverde, Á.M.; Quesada-López, T.; Villarroya, F.; Wahli, W.; Vázquez-Carrera, M. Heme-Regulated eIF2α Kinase Modulates Hepatic FGF21 and Is Activated by PPARβ/δ Deficiency. Diabetes 65:3185-99, 2016. doi: 10.2337/db16-0155.

 

Author

Identification

Zarei, M.; Barroso, E.; Palomer, X.; Dai, J.; Rada, P.; Quesada-López, T.; Escolà-Gil, J.C.; Cedó, L.; Zali, M.R.; Molaei, M.; Dabiri, R.; Vázquez, S.; Pujol, E.; Valverde, Á.M.; Villarroya, F.; Liu, Y.; Wahli, W.; Vázquez-Carrera, M. Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease. Mol. Metab. 8:117-131, 2018. doi: 10.1016/j.molmet.2017.12.008.

 

Author

Identification

Botteri, G.; Montori, M.; Gumà, A.; Pizarro, J.; Cedó, L.; Escolà-Gil, J.C.; Li, D.; Barroso, E.; Palomer, X.; Kohan, A.B.; Vázquez-Carrera, M. VLDL and apolipoprotein CIII induce ER stress and inflammation and attenuate insulin signalling via Toll-like receptor 2 in mouse skeletal muscle cells. Diabetologia 60:2262-2273, 2017. doi: 10.1007/s00125-017-4401-5.

 

Author

Identification

Vázquez-Carrera, M. Unraveling the Effects of PPARβ/δ on Insulin Resistance and Cardiovascular Disease. Trends Endocrinol. Metab. 27:319-334, 2016. doi: 10.1016/j.tem.2016.02.008

 

Author

Identification

Palomer, X.; Capdevila-Busquets, E.; Botteri, G.; Davidson, M.M.; Rodríguez, C.; Martínez-González, J.; Vidal, F.; Barroso, E.; Chan, T.O.; Feldman, A.M.; Vázquez-Carrera, M. miR-146a targets Fos expression in human cardiac cells. Dis. Model Mech. 8:1081-91, 2015. doi: 10.1242/dmm.020768.